Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: Bob Varney who wrote (1667)	4/7/1998 1:32:00 AM
From: Maxwell Smart	Read Replies (2) \| Respond to of 5736

biz.yahoo.com SpectRx Announces First Commercial Shipment of the BiliCheck Non-Invasive Bilirubin Analyzer to International Markets New device eliminates painful procedure for infants NORCROSS, Ga., April 6 /PRNewswire/ -- SpectRx, Inc. (Nasdaq: SPRX - news) today announced it has begun shipping to international distributors its BiliCheck(TM), Non-invasive Bilirubin Analyzer and BiliCal(TM) Individual Calibration Tips. The BiliCheck(TM) is the first commercially available hand- held, painless, non-invasive bilirubin analyzer designed to replace the painful heel stick blood test given to many infants. The shipments are to fill backlogged orders for the product and for distributor inventory. The initial shipments are to neonatal product distributors in Europe, Asia, Australia and New Zealand. SpectRx has signed distribution partners in 26 countries. More than 650 distributors from 75 countries have applied to sell the product. The state-of-the-art BiliCheck(TM) is the first light-based, non-invasive medical diagnostic device launched since pulse oximetry was introduced more than 20 years ago, the company believes. The BiliCheck(TM) is the first of three SpectRx products designed to replace painful, blood-based tests by harnessing light and other energy to painlessly diagnose and monitor medical conditions. ''Shipping the BiliCheck, our first product, is a major milestone for SpectRx as we continue the transition from a development stage company to a fully operational company generating revenues,'' said Mark Samuels, SpectRx president and CEO. ''This event clearly demonstrates that SpectRx has the capability to research, engineer, manufacture and distribute medical products for the future. The availability of the BiliCheck is not only a significant accomplishment for SpectRx, but for the emerging biophotonic industry. ''The BiliCheck provides immediate, low cost results at the cribside and eliminates pain for infants. Making medical diagnostics an immediate and pleasant experience is the goal of all SpectRx products,'' Mr. Samuels said. The BiliCheck(TM) Non-Invasive Bilirubin Analyzer uses light to measure bilirubin levels in newborn patients without a blood sample, regardless of skin color, gestational age or post-natal age. Excessive bilirubin may cause jaundice which affects approximately 50 percent of newborns. Bilirubin is traditionally measured in a laboratory from blood drawn from the heel of an infant. BiliCal(TM) Individual Calibration Tips are used with the BiliCheck(TM) to perform automatic calibration prior to each measurement ensuring accuracy comparable to blood analysis. The BiliCheck(TM) (CE 0413) provides rapid, point-of-care bilirubin measurements as an alternative to traditional clinical chemistry methods. These results are achieved with no trauma to the patient, no risk of infection, and reduced cost of monitoring serum bilirubin by minimizing the use of hospital personnel and supplies,. The BiliCheck(TM) is a hand-held, battery powered instrument designed for portability in the hospital, doctor's office and home health care market. The BiliCheck(TM) System comes with a compact wall mount or counter top charger base station with two rechargeable battery packs. SpectRx, Inc. is a biophotonic medical technology development company that specializes in less and non-invasive alternatives to existing blood tests and medical diagnostic and monitoring procedures. The SpectRx technologies are designed to reduce or eliminate pain, are convenient to use and provide rapid results at the point of care. In addition to the BiliCheck(TM), programs currently under development by SpectRx are a painless and bloodless personal glucose monitor with Abbott Laboratories [NYSE:ABT - news] and a non-invasive diabetes screening product with Roche Diagnostics BMC. For more information about SpectRx, visit the company's web site at www.spectrx.com The BiliCheck(TM) may not be sold in the U.S. without FDA approval. Respironics holds U.S. marketing rights to the BiliCheck(TM) and is responsible for FDA 510(k) clearance.